GlucoTrack, Inc., a medical device company, designs, develops and markets noninvasive glucose monitoring devices for people with diabetes and prediabetes in Europe and Asia Pacific. The company is headquartered in Or Yehuda, Israel.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | -20,000 |
| EBITDA | $-16.74M |
| Operating Margin | 0.00% |
| Return on Equity | -527.00% |
| Return on Assets | -150.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.34 |
| Price-to-Book | 0.65 |
| Price-to-Sales (TTM) | 526.95 |
| EV/Revenue | 420.95 |
| EV/EBITDA | -1.01 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $7.72M |
| Float | $6.25M |
| % Insiders | 11.52% |
| % Institutions | 6.61% |
Volatility is currently expanding
RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--"We are approaching the months ahead with confidence, urgency, and a clear sense of purpose," said Erik Emerson, CEO of Glucotrack.
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it acted as exclusive financial advisor in connection with a $5.5 million financing for Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK).
RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack (NASDAQ: GCTK) today announced the continued expansion of the ai² Futures Lab™ operated through its wholly owned subsidiary, Lōkahi Therapeutics™ Inc. During its first year, the ai² Futures Lab™ identified more than 45 therapeutic opportunities on a budget of approximately $33,000 and advanced five into active company discussions. These assets represent more than $500 million in prior biopharmaceutical investment and include oppor.
RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced progress in its LT-100 development strategy focused on evaluating whether a historical administration approach requiring up to 15 intradermal (ID) injections per treatment visit can be simplified to a single subcutaneous (SC) injection per visit. During a Type C meeting with the U.S. Food and Drug Administration in May 2026, the Company d.
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it served as exclusive financial advisor in the strategic business combination between Glucotrack, Inc. (Nasdaq: GCTK) and Lōkahi Therapeutics, and as exclusive placement agent for a concurrent convertible note financing of approximately $5.7 million to support the combined company's post-closing growth.
RUTHERFORD, N.J. and SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), together with its operating business Lōkahi Therapeutics™ ("Lōkahi"), a clinical-stage biopharmaceutical company advancing innovative non-opioid biologic therapies and applying its proprietary ai²™ methodology to identify and develop high-value healthcare opportunities, today announced the completion of a bridge financing designed to support the Company's strategic growth objectives, including the continued advancement of the combined Glucotrack–Lōkahi platform and other anticipated capital markets activities. The bridge financing follows the completion of the strategic business combination between Glucotrack and Lōkahi, announced on July 14, 2026.
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform
RUTHERFORD, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application titled “Methods and Systems for Continuously Monitoring the Glucose Level of a Patient.
RUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that company leadership will present on its fully implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association's (ADA) 2026 Scientific Sessions, taking place in New Orleans, June 5 – 8, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GCTK and any ticker you trade — then tracks every position and per-strategy win rate.
